$DWTX
Dogwood Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000155837024007713 Filed on May 10, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $733.7K $970.4K
YoY Change -20.19% -8.42%
% of Gross Profit
Research & Development $336.1K $343.7K
YoY Change -39.75% -30.94%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.070M $1.314M
YoY Change -27.58% -15.62%
Operating Profit -$1.070M -$1.314M
YoY Change -27.58% -15.62%
Interest Expense $19.99K $22.77K
YoY Change -44.94% -43.67%
% of Operating Profit
Other Income/Expense, Net $19.99K $22.77K
YoY Change -44.95% -43.68%
Pretax Income -$1.050M -$1.291M
YoY Change -27.14% -14.87%
Income Tax
% Of Pretax Income
Net Earnings -$1.050M -$1.291M
YoY Change -27.14% -14.87%
Net Earnings / Revenue
Basic Earnings Per Share -$0.05 -$0.07
Diluted Earnings Per Share -$0.05 -$0.07
COMMON SHARES
Basic Shares Outstanding 19.26M 19.26M
Diluted Shares Outstanding 22.90M 19.26M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.020M $2.380M
YoY Change -34.2% -55.38%
Cash & Equivalents $3.020M $2.380M
Short-Term Investments
Other Short-Term Assets $615.7K $845.1K
YoY Change -1.01% -28.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $3.636M $3.225M
YoY Change -30.24% -50.55%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $3.636M $3.225M
Total Long-Term Assets $0.00 $0.00
Total Assets $3.636M $3.225M
YoY Change -30.24% -50.55%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $217.8K $196.8K
YoY Change 1.61% 45.65%
Accrued Expenses $282.3K $373.3K
YoY Change -7.66% -9.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $500.1K $570.1K
YoY Change -3.84% 3.79%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $500.1K $570.1K
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $500.1K $570.1K
YoY Change -3.84% 3.79%
SHAREHOLDERS EQUITY
Retained Earnings -$63.81M -$62.76M
YoY Change 7.91% 8.79%
Common Stock $2.776K $1.926K
YoY Change 49.17% 5.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.136M $2.655M
YoY Change
Total Liabilities & Shareholders Equity $3.636M $3.225M
YoY Change -30.24% -50.55%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$1.050M -$1.291M
YoY Change -27.14% -14.87%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$811.8K -$937.4K
YoY Change 9.34% -44.81%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.452M
YoY Change
NET CHANGE
Cash From Operating Activities -811.8K -937.4K
Cash From Investing Activities
Cash From Financing Activities 1.452M
Net Change In Cash 640.6K -937.4K
YoY Change -186.29% -44.81%
FREE CASH FLOW
Cash From Operating Activities -$811.8K -$937.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39811
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Virios Therapeutics, Inc.
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001818844
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-4314201
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
44 Milton Avenue
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Alpharetta
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
GA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
30009
CY2024Q1 dei City Area Code
CityAreaCode
866
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
620-8655
CY2024Q1 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2024Q1 dei Trading Symbol
TradingSymbol
VIRI
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2024Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19257937
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
2379532
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3316946
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
845079
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2024Q1 us-gaap Assets Current
AssetsCurrent
3224611
CY2023Q4 us-gaap Assets Current
AssetsCurrent
4165442
CY2024Q1 us-gaap Assets
Assets
3224611
CY2023Q4 us-gaap Assets
Assets
4165442
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
196759
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
111913
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
373324
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
570083
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
358548
CY2024Q1 us-gaap Liabilities
Liabilities
570083
CY2023Q4 us-gaap Liabilities
Liabilities
358548
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19450888
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19450888
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19257937
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19257937
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
1926
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
1926
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65712269
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
65573300
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62760557
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-61469222
CY2024Q1 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
2953638
CY2023Q4 us-gaap Stockholders Equity Before Treasury Stock
StockholdersEquityBeforeTreasuryStock
4106004
CY2024Q1 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
192951
CY2023Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
192951
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299110
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299110
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2654528
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3224611
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4165442
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
343717
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
497714
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
970384
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1059573
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
1314101
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
1557287
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1314101
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1557287
CY2024Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
22766
CY2023Q1 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
40423
CY2024Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
22766
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
40423
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1291335
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1516864
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1291335
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1516864
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.07
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.07
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.08
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.08
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19257937
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19257937
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
18330390
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
18330390
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
3806894
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
138969
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1291335
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
2654528
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
7326494
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
161697
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1516864
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
5971327
CY2024Q1 us-gaap Profit Loss
ProfitLoss
-1291335
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-1516864
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
138969
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
161697
CY2024Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3417
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-150689
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
84846
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-438070
CY2024Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
126689
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-55902
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-937414
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1698450
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-937414
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-1698450
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3316946
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7030992
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
2379532
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5332542
CY2024Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1291335
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-1516864
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-937414
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1698450
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62760557
CY2024Q1 us-gaap Substantial Doubt About Going Concern Within One Year
SubstantialDoubtAboutGoingConcernWithinOneYear
true
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">The preparation of these financial statements and accompanying notes in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The Company's significant estimates and assumptions include estimated work performed but not yet billed by contract manufacturers, engineers and research organizations, the valuation of equity and stock-based related instruments, and the valuation allowance related to deferred taxes. Some of these judgments can be subjective and complex, and, consequently, actual results could differ from those estimates. Although the Company believes that its estimates and assumptions are reasonable, they are based upon information available at the time the estimates and assumptions were made. Actual results could differ from those estimates.</p>
CY2023Q4 viri Threshold Consecutive Prior Business Days
ThresholdConsecutivePriorBusinessDays
30
CY2023Q4 viri Threshold Bid Price Per Share
ThresholdBidPricePerShare
1.00
CY2023Q4 viri Additional Compliance Period
AdditionalCompliancePeriod
P180D
CY2023Q4 viri Threshold Bid Price Per Share
ThresholdBidPricePerShare
1.00
CY2023Q4 viri Threshold Consecutive Business Days
ThresholdConsecutiveBusinessDays
P10D
CY2024Q1 us-gaap Prepaid Insurance
PrepaidInsurance
533754
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
702352
CY2024Q1 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
212628
CY2023Q4 viri Prepaid Clinical Research Costs
PrepaidClinicalResearchCosts
133819
CY2024Q1 viri Prepaid Drug Purchases
PrepaidDrugPurchases
38298
CY2024Q1 viri Prepaid Services
PrepaidServices
8163
CY2023Q4 viri Prepaid Services
PrepaidServices
8766
CY2024Q1 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
52236
CY2023Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
3559
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
845079
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
848496
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q1 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2023Q4 viri Accrued Interest On Preferred Members Interest
AccruedInterestOnPreferredMembersInterest
188085
CY2024Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
93975
CY2024Q1 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
45983
CY2023Q4 viri Accrued Director Fees Current
AccruedDirectorFeesCurrent
31000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
18269
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
27550
CY2024Q1 viri Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
27012
CY2024Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
373324
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
246635
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
43000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
2000000
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
172500
CY2021Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
12.50
CY2021Q4 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2022Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
500000
CY2022Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.625
CY2023Q1 viri Warrants Exercisable Percentage
WarrantsExercisablePercentage
1
CY2023 viri Class Of Warrant Or Right Exercised
ClassOfWarrantOrRightExercised
-478625
CY2023 us-gaap Treasury Stock Shares Acquired
TreasuryStockSharesAcquired
192951
CY2023 viri Stock Issued During Period Shares Warrants Exercised
StockIssuedDuringPeriodSharesWarrantsExercised
285674
CY2024Q1 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
299110
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
193875
CY2023Q4 viri Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
11.19
CY2023 viri Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P2Y1M28D
CY2024Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
193875
CY2024Q1 viri Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
11.19
CY2024Q1 viri Class Of Warrant Or Right Remaining Term
ClassOfWarrantOrRightRemainingTerm
P1Y10M28D
CY2024Q1 viri Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
193875
CY2024Q1 viri Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
11.19
CY2024Q1 viri Class Of Warrant Or Right Weighted Average Remaining Contractual Term
ClassOfWarrantOrRightWeightedAverageRemainingContractualTerm
P1Y10M28D
CY2024Q1 viri Aggregate Intrinsic Value Of Warrants Outstanding
AggregateIntrinsicValueOfWarrantsOutstanding
0

Files In Submission

Name View Source Status
0001558370-24-007713-index-headers.html Edgar Link pending
0001558370-24-007713-index.html Edgar Link pending
0001558370-24-007713.txt Edgar Link pending
0001558370-24-007713-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
viri-20240331.xsd Edgar Link pending
viri-20240331x10q.htm Edgar Link pending
viri-20240331xex31d1.htm Edgar Link pending
viri-20240331xex31d2.htm Edgar Link pending
viri-20240331xex32d1.htm Edgar Link pending
viri-20240331xex32d2.htm Edgar Link pending
viri-20240331_cal.xml Edgar Link unprocessable
viri-20240331_def.xml Edgar Link unprocessable
viri-20240331_lab.xml Edgar Link unprocessable
viri-20240331x10q_htm.xml Edgar Link completed
viri-20240331_pre.xml Edgar Link unprocessable